Janux Therapeutics CEO gifts 123,840 shares
Janux Therapeutics, Inc. director and President and CEO David Alan Campbell reported a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Janux Therapeutics, Inc. director and President and CEO David Alan Campbell reported a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026. The transfer was recorded at $0.0000 per share, and he now directly holds 264742.0000 shares following the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 123,840 | $0.00 | $0.00 |
Key Figures
Key Terms
bona fide gift regulatory
Rule 10b5-1 trading plan regulatory
indirect ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did JANX report for CEO David Alan Campbell?
What are David Alan Campbell’s JANX holdings after the reported gift?
Was the JANX CEO’s stock gift made under a Rule 10b5-1 trading plan?
What does transaction code G mean in the JANX Form 4 for the CEO?
Is the JANX CEO’s gifted stock classified as direct or indirect ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.